NanoViricides, Inc. is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide® class of drug candidates are designed to attack enveloped virus particles and to undo them. The company is developing drugs against a number of viral diseases including H1N1 swine flu, seasonal Influenza, H5N1 bird flu, oral and genital Herpes, HIV, viral diseases of the eye which include EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus.  For more information, visit the company’s website at www.nanoviricides.com